

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Zylox-Tonbridge Medical Technology Co., Ltd.**

**歸創通橋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2190)**

### **INSIDE INFORMATION ANNOUNCEMENT APPROVAL BY THE CSRC OF THE COMPANY'S APPLICATION FOR THE FULL CIRCULATION OF H SHARES**

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on November 26, 2021, the Company received the official approval (the “**Approval**”) from the China Securities Regulatory Commission (the “**CSRC**”) regarding the implementation of the full circulation of H shares of the Company, pursuant to which up to 194,099,746 domestic unlisted shares can be converted into H shares of the Company, and their listing thereof on the Stock Exchange (the “**Conversion and Listing**”). The Approval shall be valid for 12 months from November 22, 2021.

The Company will make further announcements on the progress of the Conversion and Listing in compliance with the Listing Rules and other applicable rules.

**Completion of the Conversion and Listing is subject to the performance of other relevant procedures required by the CSRC, the Stock Exchange and other onshore and offshore regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Zylox-Tonbridge Medical Technology Co., Ltd.**  
**Dr. Jonathon Zhong Zhao**  
*Chairman and Executive Director*

Hong Kong, November 26, 2021

*As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Hai Lu and Dr. Steven Dasong Wang as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.*